JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia

Genetics and Molecular Biology

Volumn 30, Issue 2, 2007, Pages 336-338

  da Costa Reis Monte Mór, Bárbara ^a   da Cunha, Anderson Ferreira ^a   Pagnano, Kátia Bórgia Barbosa ^a   Saad, Sara Terezinha ^a   Lorand Metze, Irene ^a   Costa, Fernando Ferreira ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b NONE   (Brazil)

Author keywords

Essential thrombocythemia; Idiopathic myelofibrosis; JAK2 V617F; Myeloproliferative disorders; Polycythemia vera

Indexed keywords

GUANOSINE; JANUS KINASE 2; PROTEIN TYROSINE KINASE; THYMINE;

ARTICLE; BRAZIL; CONTROLLED STUDY; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; MAJOR CLINICAL STUDY; MYELOID METAPLASIA; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYCYTHEMIA VERA; PREVALENCE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 34547545513     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/s1415-47572007000300006     Document Type: Article

References (23)

1. Adamson JW, Fialkow PJ, Murphy S, Prchal JF and Steinmann L (1976) Polycythemia vera: Stem-cell and probable clonal origin of the disease. N Engl J Med 295:913-916.
2. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN and Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061.
3. Campbell PJ and Green AR (2005) Management of polycythemia vera and essential thrombocythemia. Hematology (Am Soc Hematol Educ Program): 201-208.
4. Campbell PJ, Griesshammer M, Dohner K, Dohner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdiles MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Briere J, Harrison CN, Green AR and Reilly JT (2006) V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Blood 107:2098-2100.
5. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN and Green AR (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 366:1945-1953.
6. Correa PN, Eskinazi D and Axelrad AA (1994) Circulating erythroid progenitors in polycythemia vera are hypersensitive to insulin-like growth factor-1 in vitro: Studies in an improved serum-free medium. Blood 83:99-112.
7. Dai CH, Krantz SB, Dessypris EN, Means Jr. RT, Horn ST and Gilbert HS (1992) Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 80:891-899.
8. Dai CH, Krantz SB, Green WF and Gilbert HS (1994) Polycythaemia vera. III. Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit receptor expression. Br J Haematol 86:12-21.
9. Fialkow PJ, Faguet GB, Jacobson RJ, Vaidya K and Murphy S (1981) Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell. Blood 58:916-919.
10. Fialkow PJ, Gartler SM and Yoshida A (1967) Clonal origin of chronic myelocytic leukemia in man. Proc Natl Acad Sci USA 58:1468-1471.
11. Jacobson RJ, Salo A and Fialkow PJ (1978) Agnogenic myeloid metaplasia: A clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 51:189-194.
12. James C, Delhommeau F, Marzac C, Teyssandier I, Couedic JP, Giraudier S, Roy L, Saulnier P, Lacroix L, Maury S, Tulliez M, Vainchenker W, Ugo V and Casadevall N (2006) Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 20:350-353.
13. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N and Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434:1144-1148.
14. Kaushansky K (2005) On the molecular origins of the chronic myeloproliferative disorders: It all makes sense. Blood 105:4187-4190.
15. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M and Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790.
16. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ and Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397.
17. McClure R, MaiMand Lasho T (2006) Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. Leukemia 20:168-171.
18. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, Vanin EF, Bodner S, Colamonici OR, van Deursen JM, Grosveld G and Ihle JN (1998) Jak2 is essential for signaling through a variety of cytokine receptors. Cell 93:385-395.
19. Prchal JF and Axelrad AA (1974) Letter: Bone-marrow responses in polycythemia vera. N Engl J Med 290:1382.
20. Spivak JL, Barosi G, Tognoni G, Barbui T, Finazzi G, Marchioli R and Marchetti M (2003) Chronic myeloproliferative disorders. Hematology (Am Soc Hematol Educ Program): 200-224.
21. Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R, Li CY, Wadleigh M, Lee SJ and Gilliland DG (2006) The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106:631-635.
22. Vainchenker W and Constantinescu SN (2005) A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of Myeloproliferative diseases. Hematology (Am Soc Hematol Educ Program): 195-200.
23. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB and Zhao ZJ (2005) Identification of an Acquired JAK2 Mutation in Polycythemia Vera. J Biol Chem 280:22788-22792.